Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Blood Coagulation Disorders

Blood Coagulation Disorders

Blood Coagulation Disorders: A comprehensive overview of disorders affecting the body's ability to clot blood, including hemophilia, thrombophilia, and other conditions.
These disorders can lead to excessive bleeding or inappropriate blood clotting, impacting patient health and quality of life.
Researchers can optimize their studies of these complex disorders using PubCompare.ai's AI-driven protocols to enhance reproducibility and accuaracy.
Discover the best research protocols from literature, preprints, and patents using advanced comparison tools, boosting research efficiency and success.

Most cited protocols related to «Blood Coagulation Disorders»

1
Defining Clinical Outcomes in COVID-19 Patients

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Activated Partial Thromboplastin Time Axilla Bacteremia Blood Blood Coagulation Disorders Bronchoalveolar Lavage Fluid Chinese Congenital Abnormality COVID 19 Echocardiography Electrocardiography Fever Heart Heart Injuries Hospital Administration Hypersensitivity Hypoproteinemia Kidney Injury, Acute pathogenesis Patients Pneumonia Pneumonia, Ventilator-Associated Respiratory Distress Syndrome, Acute Respiratory System Seafood Secondary Infections Septicemia Septic Shock Serum Albumin Sputum Times, Prothrombin Troponin I
2
Comprehensive Bleeding Phenotype Database
Bleeding score data (which were obtained for all subjects by expert-administration of the BAT) along with the von Willebrand factor (VWF) laboratory results, when available [VWF:Ag (VWF:antigen), VWF:RCo (VWF:ristocetin co-factor), FVIII:C (factor VIII coagulant)] and demographic data, were collected from 1422 normal subjects; adult data (n = 1079) were collected from individuals ≥18 years using the MCMDM-1VWD BQ (n = 294), Condensed MCMDM-1VWD BQ (n = 660), and ISTH-BAT (n = 125), while paediatric data (n = 343) were collected from individuals <18 years using the PBQ (n = 324) and ISTH-BAT (n = 19). A consistent definition of ‘normal’ was used across all studies. For adults and children, the specific wording was either individuals with no history of a known or previously diagnosed bleeding disorder or individuals with no known problem with bleeding or bruising, or both.
The data sets were merged using the Bleeding Phenotype Ontology (BPO), which was developed to explicitly represent the relationships among bleeding signs, symptoms, disorders, and treatments within the bleeding questionnaires [6 (link)]. The ontology is publicly available in the Bioportal ontology registry (http://bioportal.bioontology.org/ontologies/1166). Data elements (individual questions) from the four questionnaires were analysed to determine where they map to the BPO. From such analysis, a subset of common questions were identified and were utilized to compile data collected using different BATs for unified and standardized comparison. The aggregate data set was then stored on a MySQL database to facilitate data retrieval of various subgroups of patients. Data were separated into males and females for analysis. The mean and standard deviation (SD) were determined. Outlier values were defined as those above or below the mean ± 3 SDs. Once the outliers were removed, the middle 95th percentile was used to determine the normal range.
Elbatarny M., Mollah S., Grabell J., Bae S., Deforest M., Tuttle A., Hopman W., Clark D.S., Mauer A.C., Bowman M., Riddel J., Christopherson P.A., Montgomery R.R., Rand M.L., Coller B, & James P.D. (2014). Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia : the official journal of the World Federation of Hemophilia, 20(6), 831-835.
Publication 2014
Adult Blood Coagulation Disorders Child Chiroptera Coagulants Factor VIII Factor VIII-Related Antigen Females Limulus clotting factor C Males Patients Phenotype Ristocetin
3
Coagulation Abnormalities in Severe COVID-19
Consecutive patients with severe COVID‐19 admitted to Tongji Hospital of Huazhong University of Science and Technology in Wuhan from January 1 to February 13, 2020, were retrospectively enrolled. Exclusion criteria were a bleeding diathesis, hospital stay < 7 days, lack of information about coagulation parameters and medications, and age < 18 years. A retrospective review of the characteristics of these patients was performed through the electronic medical record system of our hospital, the medications and outcomes (28‐day mortality) were monitored up to March 13, 2020. This study was approved by the Ethics Committee of Tongji Hospital (Wuhan, China).
The diagnosis of COVID‐19 was according to World Health Organization interim guidance8 and confirmed by RNA detection of the SARS‐CoV‐2 in a clinical laboratory of the Tongji hospital. Severe COVID‐19 was defined as meeting any one of following items, according to the Diagnosis and Treatment Plan of COVID‐19 suggested by National Health Commission of China9 : Respiratory rate ≥30 breaths/min; arterial oxygen saturation ≤93% at rest; PaO2/FiO2 ≤ 300 mm Hg.
The SIC score system including prothrombin time (PT), platelet count, and sequential organ failure assessment (SOFA) was described in Table 1,6 (link) in which the SOFA score contained four items and was originally developed by an international group of experts to describe the time course of muitiple organ dysfunctions using a limited number of routinely measured variables.10 (link) Meanwhile, in our previous study,3 (link) higher D‐dimer and PT on admission were associated with poor prognosis in patients with COVID‐19. Hence these three parameters were included in this study and the results were recorded at the time the patient meeting the definition of severe COVID‐19. Anticoagulant treatment group was defined as receiving unfractionated heparin or low molecular weight heparin (LMWH) for 7 days or longer,11 (link) which was the most commonly used anticoagulant therapy for COVID‐19 in our hospital.

ISTH SIC scoring system

Table 1
ItemScoreRange
Platelet count (×109/L)1100‐150
2<100
PT‐INR11.2‐1.4
2>1.4
SOFA score11
2≥2
Total score for SIC≥4

Abbreviations: INR, International Normalized Ratio; SOFA, sequential organ failure assessment.

The coagulation tests, including PT and D‐dimer, were detected using a STA‐R MAX coagulation analyzer and original reagents (Diagnostica Stago). The platelet counts were analyzed by a Sysmex XE‐2100 hematology analyzer (Sysmex).
Normally and abnormally distributed quantitative variables were compared using the Student's t‐test and the Mann‐Whitney U test, respectively. Categorical variables were compared using the chi‐squared test. The results were given as the mean ± standard deviation, median (interquartile range), or number (percentage), wherever appropriate. Categorical and consecutive variables were evaluated by logistic regression analysis for their ability to predict 28‐day mortality. A P value of < .05 was considered statistically significant. Data were analyzed using SPSS 21.0 for Windows (SPSS Inc).
Tang N., Bai H., Chen X., Gong J., Li D, & Sun Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 18(5), 1094-1099.
Publication 2020
Anticoagulants Arteries Blood Coagulation Disorders Coagulation, Blood COVID 19 Diagnosis Ethics Committees, Clinical fibrin fragment D Heparin Heparin, Low-Molecular-Weight International Normalized Ratio Oxygen Saturation Patients Pharmaceutical Preparations Platelet Counts, Blood Prognosis Respiratory Rate SARS-CoV-2 Tests, Blood Coagulation Therapeutics Times, Prothrombin
4
Longitudinal Study of Diabetes in American Indians
Between 1965 and 2007, American Indians from the Gila River Indian Community participated in a longitudinal study of diabetes and its complications. Participants in the present trial were selected from this cohort. Eligible participants included those between 18 and 65 years old who had type 2 diabetes for at least 5 years, serum creatinine concentration <120 μmol/L (<1.4 mg/dL), serum potassium concentration ≤5.5 mEq/L, and ACR <300 mg/g on at least two of three occasions at least 1 week apart within 3 months of enrollment. Exclusion criteria included uncontrolled hypertension, pregnancy, nondiabetic kidney disease, bleeding disorders that would prevent performance of a kidney biopsy, and BMI ≥45 kg/m2. All potentially eligible members of the community were identified from the longitudinal study database and their medical records were reviewed to confirm eligibility. Of 313 patients with type 2 diabetes who were screened, 79 were ineligible, 50 declined to participate, and 14 had other reasons that prevented participation despite meeting eligibility requirements. The remaining 170 subjects were stratified into two groups, 92 with normal urinary albumin excretion and 78 with microalbuminuria. Within each stratum, subjects were assigned randomly to one of the two treatment groups (Fig. 1).
Weil E.J., Fufaa G., Jones L.I., Lovato T., Lemley K.V., Hanson R.L., Knowler W.C., Bennett P.H., Yee B., Myers B.D, & Nelson R.G. (2013). Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes. Diabetes, 62(9), 3224-3231.
Publication 2013
Albumins American Indians Biopsy Blood Coagulation Disorders Creatinine Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Eligibility Determination High Blood Pressures Kidney Kidney Diseases Patients Potassium Pregnancy Rivers Serum Urine
5
Postmarketing Survey of Recombinant Thrombomodulin
The data set was obtained from a postmarketing survey examining recombinant human-soluble thrombomodulin (TM-α; Asahi Kasei Parma Corporation, Tokyo, Japan) performed by Asahi Kasei Pharma Corporation between May 2008 and March 201011 (link) and kindly provided by the Japanese Society on Thrombosis and Hemostasis with permission. All of the cases treated in Japan during this period were registered in the survey. The survey was performed under the supervision of the Japanese Ministry of Health, Labour and Welfare (JMHW) and was conducted in accordance with the Declaration of Helsinki and Good Vigilance Practice and Good Post-marketing Study Practice. Since complete anonymisation of personal data was performed on data collection and the identification of each patient was not possible, the ethical committees waived the need to acquire informed consent from patients.
At the time of data collection, sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine consensus definition.12 (link) A total of 2516 Japanese patients with sepsis-associated coagulation disorder were registered in this survey; however, since the record of Sequential Organ Failure Assessment (SOFA) data was not mandatory, a complete data set was only obtained in 1498 cases, and all of these patients were analysed in this study. All patients were treated with TM-α (0.06 mg/kg/day for 6 days) by either intravenous bolus injection or intravenous infusion (diluted in 50 mL 0.9% saline) over 15 min via a catheter; the exclusion criteria were as follows: age less than 18 years, major bleeding, systemic inflammatory response syndrome (SIRS) score≦1, hypersensitivity to TM-α and pregnancy.
Iba T., Nisio M.D., Levy J.H., Kitamura N, & Thachil J. (2017). New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open, 7(9), e017046.
Full text: Click here
Publication 2017
Blood Coagulation Disorders Catheters Critical Care Hemostasis Hypersensitivity Intravenous Infusion Japanese Normal Saline Patients Physicians Pregnancy Septicemia Supervision Systemic Inflammatory Response Syndrome Thrombosis Wakefulness

Most recents protocols related to «Blood Coagulation Disorders»

1
Combination Therapy for LVAD Driveline Infection
Not available on PMC !

Example 4

The patient received an artificial heart (LVAD) in 2013. From fall 2015, he was initially in outpatient treatment for driveline infection. The first documented driveline treatment with ActiMaris took Place®. A few months later, inpatient admission was required for operative remediation of the infection. The finding was so pronounced that odor of the Pseudomonas infestation could be detected before the patient entered through the door. The degree of infection is shown in FIGS. 1A and 1B. Operative revision was carried out immediately. After the bleeding tendency subsided, the patient was treated with the combination method according to the invention. The infection parameters normalized within only three weeks (CRP<0.5) (see FIG. 1C) and the patient was discharged with the wound into outpatient care at his own request.

It should be noted that treatment with ActiMaris Alone® was unsuccessful for more than six months, so that the infection progressed significantly with an increase in the infection parameters. After three weeks of combination therapy, the improvement in findings shown above could be achieved with normalization of the infection values.

US11872247B2. Combination of a wound-rinsing solution and cold plasma for the treatment of wounds (2024-01-16). Westfaelische Wilhelms-Universitaet Muenster [DE]. Inventors: Heinrich Rotering [DE].
Full text: Click here
Patent 2024
Blood Coagulation Disorders Care, Ambulatory Cold Plasma Combined Modality Therapy Heart, Artificial Infection Inpatient Odors Parasitic Diseases Patients Pseudomonas Wounds
2
Pancreatic Cancer Diagnosis Biomarkers
This study included 422 patients with PC, 119 patients with benign pancreatic tumors (BPT; 39 chronic pancreatitis, 56 pancreatic serous cystadenomas, and 24 pancreatic mucinous cystadenomas), 98 patients with solid pseudo-papilloma of the pancreas (SPT), 59 patients with pancreatic neuroendocrine tumors (PNET), and 392 healthy controls (HC) from January 2015 to December 2021 at the Harbin Medical University Cancer Hospital. Eight patients with PC, 11 with other pancreatic diseases (OPT; two CP, two SPT, and seven pancreatic serous or mucinous cystadenoma), and nine HC from January 2017 to December 2021 in the Municipal Hospital Affiliated to Taizhou University were also enrolled in this study. The inclusion and exclusion criteria were as follows:1) age ≥ 18 years; 2) pathologically confirmed diagnoses of PC(adenocarcinoma, pancreatic ductal adenocarcinoma, and mucinous adenocarcinoma), neuroendocrine tumor (G1, G2, and G3), solid pseudopapillary neoplasm, chronic pancreatitis, pancreatic serous cystadenoma, and pancreatic mucinous cystadenoma; 3) R0 resection (radical surgical resection); 4) PC pathology at TNM stage I—II; 5) available clinical baseline information; 6) no antitumor therapy performed before surgery; 7) no second primary cancer; 8) no history of autoimmune disorders, hepatitis, nephropathy, coagulation disorders, or HIV infection; and 9) no acute inflammation before surgery.
Each disease group and HC from Harbin Medical University Cancer Hospital were randomly divided into training and testing sets 1 at a ratio of 4:1. The patients and HC from Municipal Hospital Affiliated to Taizhou University were used as testing set 2. Ethical approval for this study was granted by the Harbin Medical University Cancer Hospital and Municipal Hospital Affiliated to Taizhou University Ethics Committee, and all participants provided signed informed consent forms.
Gu Y., Hua Q., Li Z., Zhang X., Lou C., Zhang Y., Wang W., Cai P, & Zhao J. (2023). Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. BMC Cancer, 23, 227.
Full text: Click here
Publication 2023
Adenocarcinoma Autoimmune Diseases Benign Neoplasm Blood Coagulation Disorders Carcinoma, Pancreatic Ductal Cystadenoma, Mucinous Cystadenoma, Serous Diagnosis Ethics Committees, Clinical Hepatitis Hereditary pancreatitis HIV Infections Inflammation Islet Cell Tumor Kidney Diseases Malignant Neoplasms Mucinous Adenocarcinoma Neoplasms Neuroendocrine Tumors Operative Surgical Procedures Pancreas Pancreatic Diseases Papilloma Patients PC-II Second Primary Cancers Serum Therapeutics
3
Standardized Assessment of Bleeding and Joint Status in Nonsevere Hemophilia

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Adult Ankle Arthropathy Blood Coagulation Disorders Blood Transfusion Central Nervous System Coxa Desmopressin Epistaxis Health Personnel Hemarthrosis Hematuria Hemophilia A Joints Joints, Elbow Knee Muscle Tissue Operative Surgical Procedures Pain Measurement Patients Physical Examination Shoulder Therapy, Hormone Replacement Tooth Extraction Wounds Wounds and Injuries
4
Hepatic Artery Catheterization for Steroid Infusion
A 5-French catheter was inserted into the common hepatic artery via the right femoral artery. Before steroid injection, angiography was performed to detect any anomalies in the hepatic artery. If no replaced hepatic artery was found, the tip of the catheter was set at the proper hepatic artery. If there were 2 hepatic arteries, the catheter was positioned in the branch with the most expansive feeding area. After insertion, 1000 mg of methylprednisolone was infused over 1 hour each day for 3 days, and the catheter was removed immediately after injection on the third day. A once-daily plasma exchange was added to the regimen if a bleeding tendency was observed during this procedure.
Kuwano A., Okui T., Kohjima M., Kurokawa M., Goya T., Tanaka M., Aoyagi T., Takahashi M., Imoto K., Tashiro S., Suzuki H., Fujita N., Ushijima Y., Ishigami K., Tokunaga S., Kato M, & Ogawa Y. (2023). Transcatheter arterial steroid injection therapy improves the prognosis of patients with acute liver failure. Medicine, 102(10), e33090.
Publication 2023
Angiography Blood Coagulation Disorders Catheters Femoral Artery Hepatic Artery Methylprednisolone Plasmapheresis Steroids Treatment Protocols
5
Epidemiology of Blunt Abdominal Trauma in Egypt
The study was a concurrent cohort study, including all the BAT patients who presented to the emergency room of El Demerdash Hospital. It is a quaternary hospital, which is the surgical hospital of Ain Shams University Hospitals, Cairo, Egypt. On average, it has more than 7,000 annual emergency room visits for diagnoses related to trauma [21 ]. It has around 15,500 emergency admissions yearly, more than 2,500 of them are trauma patients, and about 800 patients are discharged within 24 hours after being stabilized and investigated. The study period was between November 2018 and October 2019. Included patients were those who presented within 24 hours after the trauma and with a Glasgow Coma Scale score greater than 8 to ensure a reliable examination, and were assessed by FAST. Exclusion criteria were as follows: BAT patients discharged without a CT scan, patients with a prehospital urinary catheterization, patients with a known history of bleeding disorders, patients with liver cirrhosis or a known history of ascites, and those with urinary diversion.
All patients underwent the usual pathway of trauma patients adopted by the hospital, which included history taking, examination (primary and secondary surveys), trauma laboratory studies, and radiologic studies, which included a FAST and an abdominopelvic CT scan. The FAST was performed for all patients by a well-trained radiology specialist registrar. The presence of hematuria was tested in the urine samples using a dipstick test (Medi-Test Combi 11, MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany).
Patients were subdivided into two groups according to the findings of the CT scan. The workflow of the patients is shown in Figure 1.
Ethical approvals
The study was approved by both the Research Ethics Committee (REC), General Surgery Department, Ain Shams University (IRB: 00006379), and the University of Maryland, Baltimore (UMB) Institutional Review Board (IRB), and it followed the tenets of the Declaration of Helsinki.
Operational definitions
“Road traffic crashes (RTC)” are all accidents related to moving vehicles, the patient may be the drivers, vehicle passengers, or pedestrians. “Falling from a height” is falling from one or more story heights, i.e., more than three meters. “Falling” is falling from less than one story height, like slips, stumbles, or falling down stairs.
Statistical analysis
The collected data were coded, tabulated, and statistically analyzed using IBM SPSS Statistics software version 22.0 (IBM Corp., Armonk, NY).
The descriptive statistics were done for the quantitative data as mean ± SD, and as number and percentage for the qualitative data. The inferential analyses were done for the quantitative variables using the independent t-test; while for the qualitative data, the inferential analyses for the independent variables were done using the chi-square test for differences between proportions and the Fisher’s exact test for the variables with small expected numbers. A p-value less than 0.05 was considered to be statistically significant, otherwise, it is non-significant.
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.
Abd-erRazik M.A., Abdel Hamid M.A., El-Shinawi M., Hirshon J.M., El-Hariri H.M, & El-Setouhy M. (2023). Combination of Focused Assessment With Sonography for Trauma (FAST) Scan and Detection of Hematuria to Exclude Intra-abdominal Injuries Following Blunt Abdominal Trauma. Cureus, 15(2), e34736.
Full text: Click here
Publication 2023
Accidents Ascites Blood Coagulation Disorders Diagnosis Emergencies Ethics Committees, Research Hematuria Liver Cirrhosis Patients Pedestrians salicylhydroxamic acid Traffic Crashes Urinalysis Urinary Catheterization Urinary Diversion Wounds and Injuries X-Ray Computed Tomography X-Rays, Diagnostic

Top products related to «Blood Coagulation Disorders»

1
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
2
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
3
Chemstrip micral by Roche
The Chemstrip Micral is a diagnostic device used for the detection of microalbuminuria, a condition characterized by small amounts of albumin in the urine. The Chemstrip Micral provides a simple and reliable method for monitoring this important biomarker.
4
Blood pressure monitor by Omron
Sourced in Japan, China, United States
The Omron Blood Pressure Monitor is a device designed to measure and display the user's blood pressure. It provides a digital readout of the systolic and diastolic blood pressure measurements, along with the heart rate.
5
Enoxaparin by Merck Group
Sourced in United States
Enoxaparin is a low-molecular-weight heparin (LMWH) used as an anticoagulant. It is a pharmaceutical product manufactured by Merck Group.
6
Papillocheck hpv genotyping test by Greiner
Sourced in Austria
PapilloCheck HPV genotyping test is a laboratory equipment product designed for the identification and differentiation of human papillomavirus (HPV) genotypes. It provides a reliable method for the detection and typing of HPV strains.
7
Human peripheral blood leukopak by STEMCELL
Sourced in Canada
Human Peripheral Blood Leukopaks are a laboratory product that contains concentrated leukocytes (white blood cells) derived from human peripheral blood. These leukocytes are isolated and enriched, providing a source of primary human immune cells for research purposes.
8
Spss version 25 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
9
Spss version 26 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Canada, Belgium, Spain
SPSS version 26 is a statistical software package developed by IBM. It is designed to perform advanced statistical analysis, data management, and data visualization tasks. The software provides a wide range of analytical tools and techniques to help users understand and draw insights from their data.
10
Pfa 100 by Siemens
Sourced in Germany, United States
The PFA-100 is a lab equipment product manufactured by Siemens. It is designed to measure platelet function in blood samples. The device uses a specialized cartridge to analyze the ability of platelets to aggregate in response to specific agonists, providing information about the platelet's activity and function.

More about "Blood Coagulation Disorders"

Blood Clotting Disorders: An Overview

Blood coagulation disorders are a complex set of conditions that impact the body's ability to clot blood properly.
These disorders can lead to either excessive bleeding (hemophilia) or inappropriate blood clotting (thrombophilia), which can have serious consequences for patient health and quality of life.
Various types of blood coagulation disorders exist, including but not limited to: hemophilia, von Willebrand disease, factor deficiencies, and thrombophilia (e.g., factor V Leiden, protein C/S deficiency).
These conditions can be inherited or acquired, and they may be influenced by factors like medication use (e.g., warfarin, enoxaparin), underlying medical conditions, or lifestyle choices.
Researchers studying blood coagulation disorders can leverage AI-driven protocols from PubCompare.ai to enhance the reproducibility and accuracy of their studies.
These advanced comparison tools allow researchers to quickly identify the best protocols from the scientific literature, preprints, and patents, boosting research efficiency and success.
In addition to PubCompare.ai, researchers may also utilize other tools and technologies in their investigations, such as SAS 9.4, SPSS version 25 or 26, the PFA-100 system, Chemstrip Micral tests, and blood pressure monitors.
By combining these resources, researchers can gain a more comprehensive understanding of blood coagulation disorders and develop improved diagnostic and treatment strategies.
Overall, the field of blood coagulation disorders is complex, but researchers have access to a growing array of technologies and resources to optimize their studies and drive advancements in this critical area of health care.